Cerebral vasospasm (CVS) is a common and severe complication of aneurysmal subarachnoid hemorrhage (aSAH). Despite the improvement in treatment of aSAH, CVS complicating aSAH has remained the main cause of death. CVS begins most often on the third day after the ictal event and reaches the maximum on the 5th-7th postictal days. Several therapeutic modalities have been employed to prevent or reverse CVS. The aim of this review is to summate all the available drug treatment modalities for vasospasm.

Objective: To explore the advantages of improved endotracheal tube and to compare it with traditional endotracheal tube. Methods: 25 patients requiring long-term mechanical ventilation patients were randomly divided into two groups: group A and group B. Group A (n=12) use improved endotracheal tube, and traditional endotracheal tube was used for Group B (n=13). The indwelling time, ICU hospitalization time, suffocation remission rate and replacement cost of the endotracheal tube were respectively compared between two groups. Results: GCS score and indwelling catheter time between two groups have no statistical significance, P > 0.05. Improved tracheal catheter is much better than traditional tracheal catheter with regards to catheter replacement cost, time of ICU stay and remission rate of suffocation, P<0.05. Conclusion: The improvement of the endotracheal tube can greatly reduce the rate of head end to stick wall, thus decreasing occurrence of severe shortness of breath, shortening the stay time of the patients in ICU at the same time, and greatly reducing the cost of hospitalization. Key words